» Articles » PMID: 18997859

Genomic Androgen Receptor-occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity

Overview
Journal PLoS One
Date 2008 Nov 11
PMID 18997859
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The androgen receptor (AR) is a steroid-activated transcription factor that binds at specific DNA locations and plays a key role in the etiology of prostate cancer. While numerous studies have identified a clear connection between AR binding and expression of target genes for a limited number of loci, high-throughput elucidation of these sites allows for a deeper understanding of the complexities of this process.

Methodology/principal Findings: We have mapped 189 AR occupied regions (ARORs) and 1,388 histone H3 acetylation (AcH3) loci to a 3% continuous stretch of human genomic DNA using chromatin immunoprecipitation (ChIP) microarray analysis. Of 62 highly reproducible ARORs, 32 (52%) were also marked by AcH3. While the number of ARORs detected in prostate cancer cells exceeded the number of nearby DHT-responsive genes, the AcH3 mark defined a subclass of ARORs much more highly associated with such genes -- 12% of the genes flanking AcH3+ARORs were DHT-responsive, compared to only 1% of genes flanking AcH3-ARORs. Most ARORs contained enhancer activities as detected in luciferase reporter assays. Analysis of the AROR sequences, followed by site-directed ChIP, identified binding sites for AR transcriptional coregulators FoxA1, CEBPbeta, NFI and GATA2, which had diverse effects on endogenous AR target gene expression levels in siRNA knockout experiments.

Conclusions/significance: We suggest that only some ARORs function under the given physiological conditions, utilizing diverse mechanisms. This diversity points to differential regulation of gene expression by the same transcription factor related to the chromatin structure.

Citing Articles

A role for androgen receptor variant 7 in sensitivity to therapy: Involvement of IGFBP-2 and FOXA1.

Biernacka K, Barker R, Sewell A, Bahl A, Perks C Transl Oncol. 2023; 34:101698.

PMID: 37307644 PMC: 10276180. DOI: 10.1016/j.tranon.2023.101698.


The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.

Kumar R, Sena L, Denmeade S, Kachhap S Nat Rev Urol. 2022; 20(5):265-278.

PMID: 36543976 PMC: 10164147. DOI: 10.1038/s41585-022-00686-y.


The role of ubiquitination in spinal and bulbar muscular atrophy.

Sengupta M, Pluciennik A, Merry D Front Mol Neurosci. 2022; 15:1020143.

PMID: 36277484 PMC: 9583669. DOI: 10.3389/fnmol.2022.1020143.


FOXA1 in prostate cancer.

Dong H, Ding L, Zhou T, Yan T, Li J, Liang C Asian J Androl. 2022; 25(3):287-295.

PMID: 36018068 PMC: 10226509. DOI: 10.4103/aja202259.


Androgen receptor-mediated transcriptional repression targets cell plasticity in prostate cancer.

Erdmann E, Ould Madi Berthelemy P, Cottard F, Angel C, Schreyer E, Ye T Mol Oncol. 2021; 16(13):2518-2536.

PMID: 34919781 PMC: 9462842. DOI: 10.1002/1878-0261.13164.


References
1.
Roh T, Ngau W, Cui K, Landsman D, Zhao K . High-resolution genome-wide mapping of histone modifications. Nat Biotechnol. 2004; 22(8):1013-6. DOI: 10.1038/nbt990. View

2.
Viger R, Mazaud Guittot S, Anttonen M, Wilson D, Heikinheimo M . Role of the GATA family of transcription factors in endocrine development, function, and disease. Mol Endocrinol. 2008; 22(4):781-98. PMC: 2276466. DOI: 10.1210/me.2007-0513. View

3.
Debes J, Tindall D . Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004; 351(15):1488-90. DOI: 10.1056/NEJMp048178. View

4.
Jackson D, Rowader K, Stevens K, Jiang C, Milos P, Zaret K . Modulation of liver-specific transcription by interactions between hepatocyte nuclear factor 3 and nuclear factor 1 binding DNA in close apposition. Mol Cell Biol. 1993; 13(4):2401-10. PMC: 359561. DOI: 10.1128/mcb.13.4.2401-2410.1993. View

5.
Thalmann G, Anezinis P, Chang S, Zhau H, Kim E, Hopwood V . Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54(10):2577-81. View